CN104224851A - Application of bifidobacterium animalis subsp. lactis CGMCC NO.9273 - Google Patents
Application of bifidobacterium animalis subsp. lactis CGMCC NO.9273 Download PDFInfo
- Publication number
- CN104224851A CN104224851A CN201410404044.0A CN201410404044A CN104224851A CN 104224851 A CN104224851 A CN 104224851A CN 201410404044 A CN201410404044 A CN 201410404044A CN 104224851 A CN104224851 A CN 104224851A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium animalis
- application
- compositions
- cgmcc
- lactis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of bifidobacterium animalis subsp. lactis with the preservation number of CGMCC NO.9273 to adjustment of body immunity functions; the application does not include treatment of diseases of human bodies or animal bodies; in addition, the invention further discloses a composition containing the bifidobacterium animalis subsp. lactis as an active component. Compared with other congeneric bifidobacteriums, the bifidobacterium animalis subsp. lactis with the preservation number of CGMCC NO.9273 is capable of adjusting the body immunity functions more effectively and has the better effects of treating and/or preventing cancers and treating and/or preventing Th1 type diseases.
Description
Technical field
The present invention relates to the application of bifidobacterium animalis acid subspecies CGMCC No.9273, be specifically related to the application of bifidobacterium animalis acid subspecies CGMCC No.9273 in conditioner body immunity function, the invention still further relates to the compositions containing bifidobacterium animalis acid subspecies CGMCC No.9273.
Background technology
Immunity is a kind of physiological function of human body, relates to nonspecific immunity and specific immunity, and nonspecific immunity does not need to contact antigen in advance, once pathogen enters body, then can remove pathogen fast.Phagocyte and natural killer cell all have removing and lethal effect, are the important members in non-specific immune systems.Specific immunity has and identifies alien material specifically and have the immunocyte (T lymphocyte and bone-marrow-derived lymphocyte) of immunological memory ability.Information Conduction the most primary between immune system is exactly cytokine, and often kind of cytokine has different stimulatory functions to different cell types, the growth promoter of their inducing cells by the specific receptor in conjunction with cell surface and functional activity.Human body relies on this identification of function " oneself " and " non-own " composition, thus destroy and repel and enter damaging cells that the antigenic substance of human body or human body itself produce and tumor cell etc., to maintain the health of human body, resist or prevent the intrusion of microorganism or parasitic infection or other undesirable biology.
Bacillus bifidus, as the physiology bacterium of human intestine, the health safeguarding host plays important effect, and bacillus bifidus can play immunological enhancement function to body by thalline and component thereof.
Summary of the invention
The object of this invention is to provide the application that a strain has more the bacillus bifidus of immunodominance.
To achieve these goals, the invention provides bifidobacterium animalis acid subspecies (the Bifidobacterium animalis subsp.lactis) application in conditioner body immunity function that deposit number is CGMCC No.9273, described application does not comprise the disease for the treatment of human body or animal body.
Preferably, described application comprises the medicine for the preparation for the treatment of and/or preventing cancer.
Preferably, described application comprises the medicine for the preparation of preventing and/or treating Th2 type disease.
On the other hand, present invention also offers containing deposit number is that bifidobacterium animalis acid subspecies (Bifidobacterium animalis subsp.lactis) of CGMCC No.9273 is as the compositions of active component.
Compared to other bacillus bifidus belonged to together, deposit number is that the bifidobacterium animalis acid subspecies of CGMCC No.9273 more effectively can regulate the immunologic function of body, show by experiment, deposit number is at least one that the bifidobacterium animalis acid subspecies of CGMCC No.9273 can improve in following index: cytophagous phagocytic rate, the multiplication capacity of splenocyte, the content of IgG in serum, strengthen the expression of TLR-2, TNF-α, IFN-γ on intestinal mucosa, and the ratio of IFN-γ/IL-4 on intestinal mucosa.Wherein, on intestinal mucosa, the enhancing of TLR-2 and TNF-alpha expression can treat and/or prevent cancer effectively, and the raising of the expression enhancing of IFN-γ and the ratio of IFN-γ/IL-4 effectively can prevent and/or treat Th2 type disease.
Other features and advantages of the present invention are described in detail in detailed description of the invention part subsequently.
Biological deposits
Bifidobacterium animalis acid subspecies (Bifidobacterium animalis subsp.lactis) of the present invention, (address: No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, China Committee for Culture Collection of Microorganisms's common micro-organisms center is deposited on June 5th, 2014, Institute of Microorganism, Academia Sinica, postcode: 100101) (depositary institution is abbreviated as CGMCC), deposit number is CGMCC No.9273.
Detailed description of the invention
Below the specific embodiment of the present invention is described in detail.Should be understood that, detailed description of the invention described herein, only for instruction and explanation of the present invention, is not limited to the present invention.
The present inventor finds, compared to other bacillus bifidus belonged to together, deposit number is that bifidobacterium animalis acid subspecies (Bifidobacterium animalis subsp.lactis) of CGMCC No.9273 more effectively can regulate the immunologic function of body, such as, improve in following index any one: cytophagous phagocytic rate, the multiplication capacity of splenocyte, the content of IgG in serum, the expression of TLR-2, TNF-α, IFN-γ on intestinal mucosa, and the ratio of IFN-γ/IL-4 on intestinal mucosa.Wherein, on intestinal mucosa, the enhancing of TLR-2 and TNF-alpha expression can treat and/or prevent cancer effectively, and the raising of the expression of IFN-γ and the ratio of IFN-γ/IL-4 effectively can prevent and/or treat Th2 type disease.
Wherein, the specific immunity of body mainly contains two classes, i.e. humoral immune reaction (Th2 type) and cell mediated immune response (Th1).Th1 cytokines (IL-2, IFN-γ) can promote cell mediated immune response, contributes to body opposing tumor, intracellular bacterial infection and viral infection.Th2 cytokines (IL-4, IL-5, IL-6) can react by humoral immunity, contribute to the antibody that body produces specific antigen, wherein, when the immunity of Th2 type is crossed strong, easily bring out the autoimmune response of body, cause autoimmune disease.The ratio of IFN-γ/IL-4 shows the differentiation of Th1/Th2 cell, and the ratio of IFN-γ/IL-4 is greater than 1, illustrates that the immunoreation that it is induced is more prone to Th1 immunity, thus can suppress the immunity of Th2 type to a certain extent.Deposit number is that the bifidobacterium animalis acid subspecies of CGMCC No.9273 can regulate the ratio of IFN-γ/IL-4 effectively, makes immunoreation be more prone to Th1 immunity.
Based on above discovery, on the one hand, the invention provides bifidobacterium animalis acid subspecies (the Bifidobacterium animalis subsp.lactis) application in conditioner body immunity function that deposit number is CGMCC No.9273, described application does not comprise the disease for the treatment of human body or animal body.
The present invention only protects to need the deposit number improving immunity of organisms to be bifidobacterium animalis acid subspecies (the Bifidobacterium animalis subsp.lactis) application in enhancing human body immunity function of CGMCC No.9273 under non-disease conditions; and when improving immunity with disease therapy for needs, application deposit number is that bifidobacterium animalis acid subspecies (Bifidobacterium animalis subsp.lactis) of CGMCC No.9273 is not within protection scope of the present invention.
According to the present invention, described application comprises the medicine and/or food of preparing enhancing human body immunity function.
In the present invention, described food can be the food of any type, such as juice product, milk product, bean product etc.Food also can be different according to the difference of edible object.Can also containing conventional additive in described food, such as spice, mineral, vitamin, stabilizing agent, thickening agent, antiseptic etc.In addition, described medicine can be prepared into different forms according to the difference of route of administration, such as, the forms such as powder, tablet, granule, capsule, solution, Emulsion, suspensoid can be prepared into, pharmaceutically acceptable adjuvant can also be comprised in described medicine, those skilled in the art can be different according to different dosage form selection adjuvant, in this not go into detail in the present invention.
Preferably, described application comprises the medicine for the preparation for the treatment of and/or preventing cancer.
Preferably, described application comprises the medicine for the preparation of preventing and/or treating Th2 type disease.
According to the present invention, described treatment Th2 type disease refers to, can treat the disease because the immunity of Th2 type causes excessively by force, or due to the excessively weak disease caused of Th1 type immunity.
According to the present invention, the kind of described medicine can be as above, and in this not go into detail in the present invention.
On the other hand, present invention also offers a kind of is that bifidobacterium animalis acid subspecies (Bifidobacterium animalis subsp.lactis) of CGMCC No.9273 is as the compositions of active component containing deposit number.
According to the present invention, the viable bacteria body in the composition containing animal bifidobacteria described above and/or dead thalline are as active component.Preferably, the viable bacteria body containing described animal bifidobacteria or the mixing thalline of viable bacteria body and dead thalline are as active component.When using the mixing thalline of viable bacteria body or dead thalline as active component, the quantity of viable bacteria body is preferably higher than the quantity of dead thalline.
In described compositions of the present invention, although described animal bifidobacteria is added in described compositions, and administration is carried out to individuality, object of the present invention can be realized, namely play the effect of immunity moderation, but under preferable case, but in order to strengthen the health-care effect of described compositions further, preferably, with compositions every gram described for benchmark, the content of described animal bifidobacteria is 10
6-10
11cFU.
According to the present invention, compositions of the present invention can exist in a variety of forms, and such as, can exist with the form of medicine, also can exist with the form of food, this determines according to the actual demand of those skilled in the art.
CFU (Colony-Forming Units, colony-forming units) refers to viable bacteria number.When viable bacteria cultivates counting, by single thalline or assemble agglomerating multiple thalline and breed the colony formed at cultured on solid medium, be called colony-forming units, with the quantity of its expression viable bacteria, can be obtained by the method for plate culture count.In the present invention, when the concentration of the dead thalline of bacillus bifidus represents with CFU/ml, after referring to the viable bacteria body death of bacillus bifidus, obtain the dead thalline of respective numbers, and be dissolved in buffer and be mixed with desired concn.
The present invention is further illustrated for following embodiment, but therefore do not limit the present invention.
In following preparation example, embodiment and comparative example:
Strain subject and condition of culture:
Bifidobacterium animalis acid subspecies A6 (Bifidobacterium animalis subsp.lactis) (hereinafter referred to as A6); Positive control strain BB12 (animal bifidobacteria, from Hansen Corp. of section), tested bacterium in 37 DEG C of Anaerobic culturel 12h, makes bacteria concentration reach 10 in MRS anaerobic liquid culture medium
9cfu/ml, bacterium liquid at room temperature collects thalline with the centrifugal 15min of 4200g, thalline physiological saline solution is resuspended wash twice after, be adjusted to variable concentrations with physiological saline solution.Those skilled in the art are it is understood that be the dead thalline of the bacillus bifidus comprising some in this bacteria suspension prepared.
Laboratory animal:
SPF level BALB/c mouse, 6 to 8 ages in week, male, body weight 18-22g, be purchased from Beijing laboratory animal Technology Co., Ltd. of company of dimension tonneau China, raise in genetically modified organism edible safety supervision and inspection center of the Ministry of Agriculture (Beijing) Animal House, room temperature 22 ± 2 DEG C, 12 hours lamp photograph/dark cycle, freely drink water and ingest.
The present invention's reagent used, culture medium composition and experiment method etc. in case of no particular description, are reagent, culture medium composition and experiment method that this area routine uses.In case of no particular description, measured below numerical value is all the meansigma methodss measuring 8 parallel sample gained under experimental conditions.
Embodiment 1-3
Mice random packet, often organize 10, after adaptability raises 7 days, each dosage group gavages the tested bacterium A60.2ml/ days of variable concentrations every day respectively, and wherein high dose group is 10
10cfu/ml (as embodiment 1), middle dosage group is 10
8cfu/ml (as embodiment 2), low dose group is 10
6cfu/ml (as embodiment 3).Gavage 7 weeks, claims a body weight weekly.
(1) drip sheet method and measure macrophage phagocytic chicken red blood cell (CRBC) phagocytic rate
After mice excision eyeball gets blood, put to death through cervical dislocation.At superclean bench separating mouse abdominal cavity cell liquid as early as possible, operate as follows.
Carefully cut off abdominal part fur, expose peritoneum, contain Hank ' the s liquid of 5% (v/v) hyclone with asepsis injector to lumbar injection 4mL.Rub gently abdominal part several under, with syringe sucking-off abdominal cavity liquid (about 2ml), wherein containing macrophage.The activity of macrophage phagocytic chicken red blood cell (CRBCs) adopts the dull and stereotyped Determination Staining of Giemsa, engulfs number with optics microscopic counting CRBC, is summarized as follows.In macrophage liquid, add hyclone makes its final concentration be 20% (v/v), and under this serum-concentration, macrophage can be adherent preferably.CRBC normal saline is made into the Cell sap of 1% (v/v).Mixed with CRBC equal-volume by macrophage liquid, after piping and druming evenly, fast drop is in the sealing ring of the slide with wax crayon or 3% (w/v) agar closed edge, makes cell mixing liquid be covered with slide.Slide is placed in 37 DEG C, 5%CO
2hatch 20 minutes in incubator, in the process, macrophage can complete the phagocytosis to CRBC.Cultivate terminate rear rapid normal saline by not adherent macrophage and not by the CRBC engulfed wash out (with suction pipe absorption normal saline blow and beat 5 times), dropping methanol fix 1 minute.Giemsa stock solution PBS buffer dilutes 8 times, is evenly added drop-wise on slide and (often opens slide 0.5mL), dyes 15 minutes.Clean with distilled water flushing, dry.Macrophage phagocytic activity CRBC number counted by engulfing under 60 times of light microscopics represents.Often open slide and count 100 macrophages, phagocytic rate for engulf CRBC in every 100 macrophages macrophage shared by percentage ratio, the results are shown in Table 1.
(2) spleen lymphocyte proliferation ability detects
The propagation of splenocyte adopts CCK-8 method to measure.Prepare splenocyte, with RPMI-1640 culture medium adjustment cell concentration to 2 × 10
6individual/ml, adds 96 orifice plates by splenocyte, every hole 100 μ l.Every hole adds 1640 culture medium that 10 μ l contain or do not contain concanavalin A, Con A (ConA, final concentration 1.5ug/ml, containing ConA is stimulation hole, and what do not contain is control wells).Each sample establishes 3 to stimulate hole and 3 control wells.Establish the blank well only adding pure culture base simultaneously.Cell at 37 DEG C, 5%CO
2incubator in cultivate 72 hours.Distance is cultivated and is terminated first 4 hours, and every hole adds 10 μ l CCK-8 reagent.After cultivation terminates, measure each hole light absorption value by microplate reader under 490nm wavelength, the Spleen cell proliferation situation rate of increase represents, by following formulae discovery, the results are shown in Table 1.
Appreciation rate=[A (adding ConA)-A (blank)]/[A (without ConA)-A (blank)] × 100%
A (adding ConA): the absorbance with the hole of cell, CCK-8 solution and ConA solution
A (blank): there is culture medium and CCK-8 solution and do not have the absorbance in the hole of cell
A (without ConA): there is cell, CCK-8 solution and do not have the absorbance in the hole of ConA solution
(3) serum IgG content measures
Mice is before slaughtering, and extract eyeball and get blood, blood sample at room temperature places blood coagulation in about 3 hours, is then placed in 4 DEG C of refrigerator overnight.By the centrifugal 10min of 1000rpm under sample room temperature, careful collection upper serum, if be mixed with erythrocyte, then recentrifuge, draws supernatant.Blood serum sample is frozen in-20 DEG C.In serum, IgG concentration ELISA method detects, and the results are shown in Table 1.
(4) mensuration of the protection of intestinal mucosal barrier cells factor
Put to death mice, open abdominal cavity, by caecum upwards 5cm get distal ileum section, cut off intestinal tube, discard rete malpighii, with coverslip scraping small intestinal mucosa, TRIzol test kit (TIANGEN Biotech (Beijing) Co., Ltd.) is used to extract total serum IgE according to its description, Reverse Transcription box (precious biological engineering (Dalian) company limited of TaKaRa) is used to be cDNA according to its description reverse transcription, RT-qPCR method measures genes of interest TLR-2, TNF-α, the expression of IFN-γ and IL-4, and the ratio calculating IFN-γ/IL-4.Wherein, RT-qPCR reacts employing 20 μ l reaction system: 2 × Ultra SYBR Mixture 10 μ l, upstream and downstream primer (10pmol/ μ l) each 0.2 μ l, cDNA2 μ l, ddH
2o7.6 μ l; Reaction condition be 95 DEG C of 30s denaturations once, 95 DEG C of 15s, 60 DEG C of 30s, 72 DEG C of 30s, 80 DEG C of 5s, 40 circulations.Wherein, measure TLR-2, TNF-α, the expression the primer of IFN-γ and IL-4 is as shown in the table, and reference gene is GAPDH.The expression of TLR-2, TNF-α, IFN-γ and IL-4 is the expression relative to GAPDH gene.Result is as shown in table 1.
| Gene | Primer sequence (5 '-3 ') |
| TLR-2 | F:TCTAAAGTCGATCCGCGACAT(SEQ?ID?No：1) |
| ? | R:CTACGGGCAGTGGTGAAAACT(SEQ?ID?No：2) |
| TNF-α | F:ACGGCATGGATCTCAAAGAC(SEQ?ID?No：3) |
| ? | R:AGATAGCAAATCGGCTGACG(SEQ?ID?No：4) |
| IFN-γ | F:AGCGGCTGACTGAACTCAGATTGTAG(SEQ?ID?No：5) |
| ? | R:GTCACAGTTTTCAGCTGTATAGGG(SEQ?ID?No：6) |
| IL-4 | F:GGTCTCAACCCCCAGCTAGT(SEQ?ID?No：7) |
| ? | R:GCCGATGATCTCTCTCAAGTGAT(SEQ?ID?No：8) |
| GAPDH | F:GTGTTCCTACCCCCAATGTGT(SEQ?ID?No：9) |
| ? | R:ATTGTCATACCAGGAAATGAGCTT(SEQ?ID?No：10) |
Comparative example 1
According to the method for embodiment 1-3, laboratory animal is processed and follow-up test, unlike, this treated animal often only gavages normal saline 0.2ml/ days, and as a control group 1, experimental result is as shown in table 1.
Comparative example 2
According to the method for embodiment 1-3, laboratory animal is processed and follow-up test, unlike, this treated animal often only gavages the BB12 of 0.2ml/ days, and as a control group 2, experimental result is as shown in table 1.
Table 1
| ? | Embodiment 1 | Embodiment 2 | Embodiment 3 | Comparative example 1 | Comparative example 2 |
| The phagocytic rate (%) of macrophage phagocytic CRBC | 30.4 | 36.4 | 30.36 | 27.54 | 29.05 |
| Spleen lymphocyte proliferation rate (%) | 16.13 | 9.52 | 9.28 | 9.14 | 9.23 |
| Serum IgG content (mg/ml) | 2.82 | 2.74 | 2.23 | 2.02 | 2.11 |
| The expression of TLR-2 | 2.09 | 1.62 | 1.68 | 1.00 | 1.43 |
| The expression of TNF-α | 1.64 | 1.29 | 1.45 | 1.00 | 1.10 |
| The expression of IFN-γ | 3.37 | 3.62 | 1.99 | 1.00 | 1.80 |
| The expression of IL-4 | 0.86 | 0.62 | 0.80 | 1.00 | 0.80 |
| IFN-γ/IL-4 | 3.91 | 5.83 | 2.48 | 1 | 2.25 |
As can be seen from the data in table 1, at identical conditions, compared to the BB12 with good immunologic function generally acknowledged belonged to together, deposit number is that bifidobacterium animalis acid subspecies (Bifidobacterium animalis subsp.lactis) of CGMCC No.9273 more effectively can improve the immunity of body, and the content of TLR-2 and TNF-α can be increased in necessarily and effectively level, and it is as well known to those skilled in the art, TNF-α can kill and wound cancerous cell effectively, TLR-2 is the expressed receptor that macrophage accepts probiotic bacteria stimulation, the increase reflection macrophage activation level of TLR-2 strengthens, thus the ability of killing and wounding cancerous cell is improved.Therefore, compared to other bacillus bifiduss belonged to together, deposit number is that bifidobacterium animalis acid subspecies (Bifidobacterium animalis subsp.lactis) of CGMCC No.9273 more effectively can be used for the treatment of cancer.Further, effectively can regulate the ratio of IFN-γ/IL-4, make immunity of organism be more prone to the immunity of Th1 type.
More than describe the preferred embodiment of the present invention in detail; but the present invention is not limited to the detail in above-mentioned embodiment, within the scope of technical conceive of the present invention; can carry out multiple simple variant to technical scheme of the present invention, these simple variant all belong to protection scope of the present invention.
It should be noted that in addition, each the concrete technical characteristic described in above-mentioned detailed description of the invention, in reconcilable situation, can be combined by any suitable mode.In order to avoid unnecessary repetition, the present invention illustrates no longer separately to various possible compound mode.
In addition, also can carry out combination in any between various different embodiment of the present invention, as long as it is without prejudice to thought of the present invention, it should be considered as content disclosed in this invention equally.
Claims (9)
1. deposit number is bifidobacterium animalis acid subspecies (the Bifidobacterium animalis subsp.lactis) application in conditioner body immunity function of CGMCC No.9273, and described application does not comprise the disease for the treatment of human body or animal body.
2. application according to claim 1, wherein, described conditioner body immunity function comprises at least one improved in following index:
Cytophagous phagocytic rate, the multiplication capacity of splenocyte, the content of IgG in serum, the expression of TLR-2, TNF-α, IFN-γ on intestinal mucosa, and the ratio of IFN-γ/IL-4 on intestinal mucosa.
3. application according to claim 1 and 2, wherein, described application comprises the medicine and/or food of preparing enhancing human body immunity function.
4. application according to claim 3, wherein, described application comprises the medicine for the preparation for the treatment of and/or preventing cancer.
5. application according to claim 3, wherein, described application comprises the medicine for the preparation of preventing and/or treating Th2 type disease.
6. be the compositions of bifidobacterium animalis acid subspecies (Bifidobacterium animalis subsp.lactis) as active component of CGMCC No.9273 containing deposit number.
7. compositions according to claim 6, wherein, described compositions contains the viable bacteria body of described animal bifidobacteria and/or dead thalline as active component.
8. the compositions according to claim 6 or 7, wherein, with compositions every gram described for benchmark, the content of described animal bifidobacteria is 10
6-10
11cFU.
9. compositions according to claim 6, wherein, described compositions comprises medicine and/or food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410404044.0A CN104224851B (en) | 2014-08-15 | 2014-08-15 | The application of bifidobacterium animalis acid subspecies CGMCC No.9273 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410404044.0A CN104224851B (en) | 2014-08-15 | 2014-08-15 | The application of bifidobacterium animalis acid subspecies CGMCC No.9273 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104224851A true CN104224851A (en) | 2014-12-24 |
| CN104224851B CN104224851B (en) | 2018-08-24 |
Family
ID=52214330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410404044.0A Active CN104224851B (en) | 2014-08-15 | 2014-08-15 | The application of bifidobacterium animalis acid subspecies CGMCC No.9273 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104224851B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617096A (en) * | 2017-02-15 | 2017-05-10 | 中国农业大学 | Bifidobacterium capable of enhancing pancreatic function and application of bifidobacterium |
| CN107802659A (en) * | 2016-09-08 | 2018-03-16 | 潍坊华英生物科技有限公司 | A kind of intravenous injection for strengthening immunologic function |
| WO2019010255A1 (en) * | 2017-07-05 | 2019-01-10 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis |
| CN110846241A (en) * | 2018-08-20 | 2020-02-28 | 中国农业大学 | Bifidobacterium animalis capable of decomposing and utilizing human milk oligosaccharide, culture method thereof and food or medicine |
| CN113583923A (en) * | 2021-09-28 | 2021-11-02 | 中国农业大学 | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression |
| CN114225024A (en) * | 2021-12-29 | 2022-03-25 | 北京创世客生物技术有限公司 | A probiotic medicine or health product for treating diseases |
| CN114437959A (en) * | 2021-11-29 | 2022-05-06 | 内蒙古普泽动保生物技术有限公司 | Bifidobacterium animalis and application thereof in antioxidation and immunity improvement |
| CN115245532A (en) * | 2021-06-25 | 2022-10-28 | 丰宁水星乳品有限责任公司 | Almond powder product with weight-losing and lipid-lowering functions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275893A (en) * | 2013-05-06 | 2013-09-04 | 哈尔滨美华生物技术股份有限公司 | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants |
| CN103874427A (en) * | 2011-07-12 | 2014-06-18 | 雀巢产品技术援助有限公司 | Probiotic for administration to healthy young mammals during the weaning period for improving tolerance to newly introduced food stuffs |
-
2014
- 2014-08-15 CN CN201410404044.0A patent/CN104224851B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103874427A (en) * | 2011-07-12 | 2014-06-18 | 雀巢产品技术援助有限公司 | Probiotic for administration to healthy young mammals during the weaning period for improving tolerance to newly introduced food stuffs |
| CN103275893A (en) * | 2013-05-06 | 2013-09-04 | 哈尔滨美华生物技术股份有限公司 | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants |
Non-Patent Citations (1)
| Title |
|---|
| GIULIANO RIZZARDINI: "Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12 ®and Lactobacillus paracasei ssp. paracasei,L. casei 431® in an influenza vaccination model: a randomised, double-blind,placebo-controlled study", 《BRITISH JOURNAL OF NUTRITION》 * |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107802659A (en) * | 2016-09-08 | 2018-03-16 | 潍坊华英生物科技有限公司 | A kind of intravenous injection for strengthening immunologic function |
| CN107802659B (en) * | 2016-09-08 | 2020-08-25 | 潍坊华英生物科技有限公司 | Intravenous injection for enhancing immunologic function |
| CN106617096A (en) * | 2017-02-15 | 2017-05-10 | 中国农业大学 | Bifidobacterium capable of enhancing pancreatic function and application of bifidobacterium |
| CN106617096B (en) * | 2017-02-15 | 2020-12-18 | 中国农业大学 | Bifidobacterium for enhancing pancreatic islet function and application thereof |
| KR20200024911A (en) * | 2017-07-05 | 2020-03-09 | 에벨로 바이오사이언시즈, 인크. | Bifidobacterium animal ssp. Cancer Treatment Compositions and Methods Using Lactis |
| CN111356464A (en) * | 2017-07-05 | 2020-06-30 | 伊夫罗生物科学公司 | Compositions and methods for treating cancer using bifidobacterium animalis subsp |
| JP2020526581A (en) * | 2017-07-05 | 2020-08-31 | エヴェロ バイオサイエンシズ，インコーポレーテッド | Compositions and Methods for Treating Cancer with Bifidobacterium animalis ssp. Ractis. |
| US10792314B2 (en) | 2017-07-05 | 2020-10-06 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using Bifidobacterium animalis ssp. lactis |
| WO2019010255A1 (en) * | 2017-07-05 | 2019-01-10 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis |
| US10576111B2 (en) | 2017-07-05 | 2020-03-03 | Evelo Biosciences, Inc. | Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097 |
| KR102563191B1 (en) * | 2017-07-05 | 2023-08-02 | 에벨로 바이오사이언시즈, 인크. | Bifidobacterium animalis ssp. Cancer treatment composition and method using lactis |
| JP7254786B2 (en) | 2017-07-05 | 2023-04-10 | エヴェロ バイオサイエンシズ，インコーポレーテッド | Compositions and methods for treating cancer with Bifidobacterium animalis ssp.lactis |
| CN110846241A (en) * | 2018-08-20 | 2020-02-28 | 中国农业大学 | Bifidobacterium animalis capable of decomposing and utilizing human milk oligosaccharide, culture method thereof and food or medicine |
| CN115245532A (en) * | 2021-06-25 | 2022-10-28 | 丰宁水星乳品有限责任公司 | Almond powder product with weight-losing and lipid-lowering functions |
| CN113583923A (en) * | 2021-09-28 | 2021-11-02 | 中国农业大学 | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression |
| CN113583923B (en) * | 2021-09-28 | 2021-12-07 | 中国农业大学 | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression |
| CN114437959A (en) * | 2021-11-29 | 2022-05-06 | 内蒙古普泽动保生物技术有限公司 | Bifidobacterium animalis and application thereof in antioxidation and immunity improvement |
| CN114437959B (en) * | 2021-11-29 | 2022-11-18 | 内蒙古普泽动保生物技术有限公司 | Bifidobacterium animalis and application thereof in antioxidation and immunity improvement |
| CN114225024B (en) * | 2021-12-29 | 2022-08-19 | 山东健袖生态科技有限公司 | Probiotic medicament for treating diseases |
| CN114225024A (en) * | 2021-12-29 | 2022-03-25 | 北京创世客生物技术有限公司 | A probiotic medicine or health product for treating diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104224851B (en) | 2018-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104224851A (en) | Application of bifidobacterium animalis subsp. lactis CGMCC NO.9273 | |
| CN110893195B (en) | Lactobacillus paracasei ET-22 with function of relieving intestinal inflammation | |
| JP6909152B2 (en) | Compositions Containing Bacterial Strains | |
| Kiadaliri et al. | Effects of feeding with red algae (Laurencia caspica) hydroalcoholic extract on antioxidant defense, immune responses, and immune gene expression of kidney in rainbow trout (Oncorhynchus mykiss) infected with Aeromonas hydrophila | |
| CN108495642A (en) | Include the composition of bacterium bacterial strain | |
| JP4521687B2 (en) | Probiotics, Propionibacterium ienseni 702 | |
| Yang et al. | Oral administration of live Bifidobacterium substrains isolated from healthy centenarians enhanced immune function in BALB/c mice | |
| CN108513545A (en) | Include the composition of bacterium bacterial strain | |
| CN110893194B (en) | New application of bifidobacterium lactis BL-99 in inhibiting intestinal inflammation | |
| CN104523762B (en) | The application of lactobacillus paracasei with anti-allergic effects and functional food composition and preparation method thereof | |
| TW201907931A (en) | Composition comprising a bacterial strain | |
| CN110892940A (en) | New application of lactobacillus paracasei K56 in relieving intestinal inflammation | |
| CN101649303B (en) | Bifidobacterium, application thereof and food composition containing same | |
| CN101171019A (en) | Immune function modulating agents | |
| CN106413724B (en) | Lactobacillus rhamnosus RHT-3201 conjugated with polysaccharide polymer binder and uses thereof | |
| JPWO2011111734A1 (en) | Lactic acid bacteria-containing preparation | |
| CN101144062A (en) | Lactobacillus casei strain and application for products thereof in bird immunity | |
| KR20200071123A (en) | Composition for enhancing immune function of T cells and preparation method thereof | |
| CN102091099A (en) | Application of bacillus coagulans in preparing medicine for treating inflammatory bowel disease | |
| JP2021524751A (en) | Composition and its use | |
| CN105535650A (en) | Probiotic composition with anti-tumor function as well as preparation method and application thereof | |
| CN101138573A (en) | Application of clostridium butyricum and condensate bacillus in the preparation of medicament for treating inflammatory bowel disease | |
| CN103622952A (en) | Application of arctigenin in preparation of anti-infectious immunity drugs | |
| Hao et al. | The biological regulatory activities of Flammulina velutipes polysaccharide in mice intestinal microbiota, immune repertoire and heart transcriptome | |
| Georgieva et al. | Probiotics and immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ren Fazheng Inventor after: Zhu Yuanbo Inventor after: Guo Huiyuan Inventor after: Zhao Liang Inventor before: Zhu Yuanbo Inventor before: Ren Fazheng Inventor before: Guo Huiyuan Inventor before: Zhao Liang |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160823 Address after: 100083 Haidian District Qinghua East Road, No. 17, Beijing Applicant after: China Agricultural University Address before: 100083 Haidian District Qinghua East Road,, No. 17, China Agricultural University Applicant before: Ren Fazheng |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |